Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Merck
McKesson
Boehringer Ingelheim
Dow

Last Updated: August 19, 2022

VARITHENA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Varithena patents expire, and when can generic versions of Varithena launch?

Varithena is a drug marketed by Provensis and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and two patent family members in thirty countries.

The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this compound. Additional details are available on the polidocanol profile page.

DrugPatentWatch® Generic Entry Outlook for Varithena

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 12, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for VARITHENA
International Patents:102
US Patents:5
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 60
Clinical Trials: 5
Patent Applications: 3,109
Formulation / Manufacturing:see details
Drug Prices: Drug price information for VARITHENA
What excipients (inactive ingredients) are in VARITHENA?VARITHENA excipients list
DailyMed Link:VARITHENA at DailyMed
Drug patent expirations by year for VARITHENA
Drug Prices for VARITHENA

See drug prices for VARITHENA

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VARITHENA
Generic Entry Date for VARITHENA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VARITHENA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
OhioHealthPhase 4
BTG International Inc.Phase 4
Boston Scientific CorporationPhase 4

See all VARITHENA clinical trials

US Patents and Regulatory Information for VARITHENA

VARITHENA is protected by five US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VARITHENA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VARITHENA

Combination filter assembly
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Therapeutic foam
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES

Apparatus and method for dispensing foam
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE

Apparatus and method for dispensing foam
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Aerosol valve
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-002 Dec 21, 2017 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VARITHENA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 See Plans and Pricing See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 See Plans and Pricing See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 See Plans and Pricing See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 See Plans and Pricing See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 See Plans and Pricing See Plans and Pricing
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VARITHENA

When does loss-of-exclusivity occur for VARITHENA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Austria

Patent: 9863
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 12530
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 45533
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 45533
Estimated Expiration: See Plans and Pricing

Poland

Patent: 45533
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 45533
Estimated Expiration: See Plans and Pricing

Spain

Patent: 66399
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VARITHENA around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0656203 MICROMOUSSE INJECTABLE CONTENANT UN AGENT SCLEROSANT (INJECTABLE MICROFOAM CONTAINING A SCLEROSING AGENT) See Plans and Pricing
Brazil PI0414281 aparelho e m├ętodo para liberar espuma See Plans and Pricing
Japan 2011136192 METHOD FOR DISPENSING FOAM See Plans and Pricing
Slovenia 1694292 See Plans and Pricing
Germany 60127290 See Plans and Pricing
China 1925842 Therapeutic foam See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Merck
Boehringer Ingelheim
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.